Show simple item record

dc.contributor.authorQuinn, Kaitlin A
dc.contributor.authorMonti, Sara
dc.contributor.authorChristensen, Robin
dc.contributor.authorJayne, David
dc.contributor.authorLangford, Carol A
dc.contributor.authorLanier, Georgia E
dc.contributor.authorMahr, Alfred
dc.contributor.authorPagnoux, Christian
dc.contributor.authorShea, Beverley
dc.contributor.authorTugwell, Peter
dc.contributor.authorViðarsdóttir, Maria Bjork
dc.contributor.authorTomasson, Gunnar
dc.contributor.authorMerkel, Peter A
dc.date.accessioned2021-11-17T00:30:19Z
dc.date.available2021-11-17T00:30:19Z
dc.date.issued2021-10
dc.identifier.issn0049-0172
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/330683
dc.description.abstractOBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group aims to develop composite response criteria for ANCA-Associated Vasculitis (AAV). METHODS: The project follows the OMERACT approach for composite measures: (i) choose relevant domains; (ii) define high-quality instruments; (iii) decide on a scoring system approach; (iv) put through the OMERACT Filter 2.1 for validation. RESULTS: A systematic literature review of outcome measures used in clinical trials in AAV and an international Delphi exercise among patients with AAV and clinician-investigators with expertise in AAV have been completed to inform the candidate domains/instruments for the composite response criteria, which are the first two steps in the OMERACT approach for developing composite measures. Results of the systematic literature review and Delphi were presented at the OMERACT 2020 virtual workshop, and feedback was received on the next steps of the project, including the development of a scoring system approach. CONCLUSION: The ultimate goal of this project is to develop validated composite response criteria for use in clinical trials of AAV.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherElsevier BV
dc.rightsAll rights reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.titleDeveloping a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.
dc.typeArticle
prism.endingPage1138
prism.issueIdentifier5
prism.publicationDate2021
prism.publicationNameSemin Arthritis Rheum
prism.startingPage1134
prism.volume51
dc.identifier.doi10.17863/CAM.78128
dcterms.dateAccepted2021-07-05
rioxxterms.versionofrecord10.1016/j.semarthrit.2021.07.001
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-10
dc.contributor.orcidJayne, David [0000-0002-1712-0637]
dc.identifier.eissn1532-866X
rioxxterms.typeJournal Article/Review
cam.issuedOnline2021-07-08
cam.orpheus.success2021-11-16 - Embargo set during processing via Fast-track
rioxxterms.freetoread.startdate2022-10-31


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record